ClinicalTrials.gg
Active, not recruitingNCT07424144CEREN-3Updated Oct 13, 2026

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

A Phase 3 interventional study of Itepekimab (SAR440340) and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi. Active, not recruiting at 46 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026First sites in 4 new countries24 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Nasal Polyps by Sanofi — none open to participants now, 4 under way, 3 of them phase 3. Nasal Polyps · Sanofi.

Enrollment
10th of 12
59 · median 69
Started
2026
with 1 other
Phase 3
7 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Nasal Polyps by Sanofi, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 12th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

None of the 13 studies in Nasal Polyps by Sanofi is open now. The open studies under Nasal Polyps, anywhere →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Nasal Polyps by Sanofi as a file.
02

Study summary

This is a double-blind, parallel-group, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.

The primary purpose of this study is to evaluate safety and tolerability of both new or continued treatment with itepekimab 300 mg SC high dose or itepekimab 300 mg SC low dose in participants with CRSwNP having completed the intervention period of the clinical studies EFC18418 or EFC18419. A secondary purpose of this study is to provide efficacy outcomes beyond the intervention period of the parent trials EFC18418 and EFC18419.

Study details include:

  • The study duration will be up to 72 weeks.
  • The intervention duration will be 52 weeks.
  • A follow-up period of 20 weeks will be conducted.
  • The number of visits will be 8 and the number of phone contacts will be 4.
03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with CRSwNP who completed the 52-weeks intervention period in a previous itepekimab CRSwNP Phase 3 clinical study (ie, EFC18418 or EFC18419) and for which an EOT visit occurred no later than 5 days before the enrollment visit of this study.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a women of (WOCBP), OR
    • Is a WOCBP who agrees to follow the guidance during the intervention period and for at least 20 weeks after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Diagnosis of a during parent study, except a squamous or basal cell carcinoma of the skin.
  • Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an status.
  • Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study.
  • Any other situation that led to a permanent premature IMP discontinuation in parent trials.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Itepekimab high dose

    Subcutaneous (SC) administration of Itepekimab high dose for 52 weeks

    Drug: Itepekimab (SAR440340)

  • Experimental
    Itepekimab low dose

    SC administration of Itepekimab low dose for 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Placebo

Interventions

  • Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs), serious adverse events (SAEs), AEs leading to death, and AEs leading to permanent treatment discontinuation

    All AEs (serious or nonserious) will be collected from the signing of the ICF until end of study (EOS) visit

    Time frame: Baseline to EOS (Week 72)

Secondary outcomes

  1. Change from baseline of the parent studies (EFC18418, EFC18419) in endoscopic NPS

    The Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).

    Time frame: Baseline to Week 52

  2. Change from baseline of the parent studies (EFC18418, EFC18419) in NCS

    The Nasal Congestion Score (NCS) is scored using a 0 to 3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms.

    Time frame: Baseline to EOS (Week 72)

  3. Functional itepekimab concentration in serum

    Time frame: Baseline to EOS (Week 72)

  4. Incidence of treatment-emergent anti-drug antibody (ADA) responses

    Time frame: Baseline to EOS (Week 72)

  5. Proportion of participants with CRSwNP requiring systemic corticosteroid(s) (SCS) or surgery for chronic rhinosinusitis (CRS)

    Time frame: Baseline up to Week 52

  6. Annualized rate of SCS course or surgery for CRS

    Time frame: Baseline up to Week 52

07

Study locations

46 sites
  • Velocity Clinical Research - San Diego- Site Number : 8402041
    La Mesa, California 91942, United States
  • Allergy, Asthma and Clinical Research- Site Number : 8402002
    Oklahoma City, Oklahoma 73120, United States
  • Ear and Sinus Institute- Site Number : 8402048
    Fort Worth, Texas 76104, United States
  • Investigational Site Number : 0321004
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0321001
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0321003
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0362001
    Spearwood, Western Australia 6163, Australia
  • Investigational Site Number : 0401005
    Graz, 8036, Austria
  • Investigational Site Number : 1241001
    Québec, Quebec G1V 4G5, Canada
  • Investigational Site Number : 1242003
    Québec, Quebec G1V 4W2, Canada
  • Investigational Site Number : 1242012
    Québec, Quebec G2J 0C4, Canada
  • Investigational Site Number : 1522001
    Concepción, Biobio 4070094, Chile
  • Investigational Site Number : 1521003
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1521004
    Lo Barnechea, Reg Metropolitana de Santiago 7691236, Chile
  • Investigational Site Number : 1521001
    Puente Alto, Reg Metropolitana de Santiago 8207257, Chile
  • Investigational Site Number : 1522003
    Santiago, Reg Metropolitana de Santiago 7500505, Chile
  • Investigational Site Number : 1521002
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1562012
    Baotou, 014040, China
  • Investigational Site Number : 1562001
    Beijing, 100730, China
  • Investigational Site Number : 1562004
    Chengdu, 610017, China
  • Investigational Site Number : 1562002
    Jinan, 250022, China
  • Investigational Site Number : 1562008
    Jingzhou, 434020, China
  • Investigational Site Number : 1562013
    Nanning, 530021, China
  • Investigational Site Number : 1562006
    Shenyang, 110004, China
  • Investigational Site Number : 1562010
    Taiyuan, 030001, China
  • Investigational Site Number : 1562014
    Taiyuan, 030001, China
  • Investigational Site Number : 1562009
    Wuhan, 430060, China
  • Investigational Site Number : 1562007
    Zibo, 255036, China
  • Investigational Site Number : 2032002
    Hradec Králové, 500 05, Czechia
  • Investigational Site Number : 2032003
    Pardubice, 532 03, Czechia
  • Investigational Site Number : 2032004
    Prague, 100 34, Czechia
  • Investigational Site Number : 2032001
    Prague, 150 06, Czechia
  • Investigational Site Number : 3482005
    Budapest, 1026, Hungary
  • Investigational Site Number : 3481002
    Budapest, 1046, Hungary
  • Investigational Site Number : 3481001
    Pécs, 7621, Hungary
  • Investigational Site Number : 6162004
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6161004
    Wroclaw, Lower Silesian Voivodeship 53-301, Poland
  • Investigational Site Number : 6162001
    Bielsko-Biala, Silesian Voivodeship 43-309, Poland
  • Investigational Site Number : 6201003
    Guimarães, 4800-055, Portugal
  • Investigational Site Number : 6201002
    Porto, 3814-501, Portugal
  • Investigational Site Number : 4101003
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 4101002
    Seoul, Seoul-teukbyeolsi 06351, South Korea
  • Investigational Site Number : 4101001
    Seoul, Seoul-teukbyeolsi 07061, South Korea
  • Investigational Site Number : 8262002
    Wigan, Lancashire Wn6 9ep, United Kingdom
  • Investigational Site Number : 8262001
    London, London, City of W2 1NY, United Kingdom
  • Investigational Site Number : 8261004
    Bradford, BD9 6DA, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 11 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Mar 12, 2026
Primary completionEst.
Feb 17, 2027
CompletionEst.
Feb 17, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added, 1 site removed — first sites in Argentina, Austria, Poland and Portugal
Show 24 added (5 China, 3 Argentina, 3 Czechia, 3 Poland, 2 Chile, 2 Hungary, 2 Portugal, 1 United States, 1 Austria, 1 South Korea, 1 United Kingdom)
  • Ear and Sinus Institute- Site Number : 8402048 · Fort Worth, United States
  • Investigational Site Number : 0321004 · Rosario, Argentina
  • Investigational Site Number : 0321001 · Buenos Aires, Argentina
  • Investigational Site Number : 0321003 · Mendoza, Argentina
  • Investigational Site Number : 0401005 · Graz, Austria
  • Investigational Site Number : 1521004 · Lo Barnechea, Chile
  • Investigational Site Number : 1521001 · Puente Alto, Chile
  • Investigational Site Number : 1562002 · Jinan, China
  • Investigational Site Number : 1562013 · Nanning, China
  • Investigational Site Number : 1562014 · Taiyuan, China
  • Investigational Site Number : 1562009 · Wuhan, China
  • Investigational Site Number : 1562007 · Zibo, China
  • Investigational Site Number : 2032002 · Hradec Králové, Czechia
  • Investigational Site Number : 2032003 · Pardubice, Czechia
  • Investigational Site Number : 2032004 · Prague, Czechia
  • Investigational Site Number : 3482005 · Budapest, Hungary
  • Investigational Site Number : 3481001 · Pécs, Hungary
  • Investigational Site Number : 6162004 · Poznan, Poland
  • Investigational Site Number : 6161004 · Wroclaw, Poland
  • Investigational Site Number : 6162001 · Bielsko-Biala, Poland
  • Investigational Site Number : 6201003 · Guimarães, Portugal
  • Investigational Site Number : 6201002 · Porto, Portugal
  • Investigational Site Number : 4101002 · Seoul, South Korea
  • Investigational Site Number : 8262001 · London, United Kingdom
Show 1 removed
  • Investigational Site Number : 1521001 · Santiago, Chile
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    24 sites added, 1 site removed — first sites in Argentina, Austria, Poland and Portugal
    Show 24 added (5 China, 3 Argentina, 3 Czechia, 3 Poland, 2 Chile, 2 Hungary, 2 Portugal, 1 United States, 1 Austria, 1 South Korea, 1 United Kingdom)
    • Ear and Sinus Institute- Site Number : 8402048 · Fort Worth, United States
    • Investigational Site Number : 0321004 · Rosario, Argentina
    • Investigational Site Number : 0321001 · Buenos Aires, Argentina
    • Investigational Site Number : 0321003 · Mendoza, Argentina
    • Investigational Site Number : 0401005 · Graz, Austria
    • Investigational Site Number : 1521004 · Lo Barnechea, Chile
    • Investigational Site Number : 1521001 · Puente Alto, Chile
    • Investigational Site Number : 1562002 · Jinan, China
    • Investigational Site Number : 1562013 · Nanning, China
    • Investigational Site Number : 1562014 · Taiyuan, China
    • Investigational Site Number : 1562009 · Wuhan, China
    • Investigational Site Number : 1562007 · Zibo, China
    • Investigational Site Number : 2032002 · Hradec Králové, Czechia
    • Investigational Site Number : 2032003 · Pardubice, Czechia
    • Investigational Site Number : 2032004 · Prague, Czechia
    • Investigational Site Number : 3482005 · Budapest, Hungary
    • Investigational Site Number : 3481001 · Pécs, Hungary
    • Investigational Site Number : 6162004 · Poznan, Poland
    • Investigational Site Number : 6161004 · Wroclaw, Poland
    • Investigational Site Number : 6162001 · Bielsko-Biala, Poland
    • Investigational Site Number : 6201003 · Guimarães, Portugal
    • Investigational Site Number : 6201002 · Porto, Portugal
    • Investigational Site Number : 4101002 · Seoul, South Korea
    • Investigational Site Number : 8262001 · London, United Kingdom
    Show 1 removed
    • Investigational Site Number : 1521001 · Santiago, Chile
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07424144
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Mar 12, 2026
Primary completion
Feb 17, 2027 (estimated)
Completion
Feb 17, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion